New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
16:12 EDTXOMAXOMA says Phase 3 PATH trial meets primary endpoint
XOMA announced the 837-patient Phase 3 PATH trial of perindopril arginine combined with amlodipine besylate is statistically significantly superior to either compound alone in reducing both sitting diastolic and sitting systolic blood pressure after six weeks of treatment. This FDC, containing a patent-protected proprietary form of perindopril, was licensed by XOMA as part of a U.S. commercial and development rights agreement signed with Servier for their perindopril franchise. Servier markets the fixed-dose combination product, COVERAM, in 91 countries outside the U.S. The FDC appeared to be well tolerated in the trial, and there were no unexpected serious adverse events reported. The most common adverse events included mild to moderate edema, cough and headache, which are known side effects of the individual components of the FDC, the company said.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
11:06 EDTXOMAXOMA price target raised to $1.50 from $1 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for XOMA (XOMA) to $1.50 after the company partnered a preclinical TGF-beta antibody with Novartis (NVS) for $37M upfront and up to $480M in milestones. The payment brings XOMA's pro forma cash to $88M, enabling the company to advance its endocrine antibody pipeline, including lead candidate XOMA 358 for hyperinsulinism disorders, Tenthoff tells investors in a research note. The analyst keeps a Neutral rating on the name. The stock is up 20c to 95c in early trading.
09:20 EDTXOMAOn The Fly: Pre-market Movers
HIGHER: XOMA (XOMA), up 55.7% after announcing an agreement for anti-TGFb program with Novartis (NVS)... Sarepta Therapeutics (SRPT), up 10.6% after announcing additional clinical efficacy and safety data from the company's Phase IIb program of eteplirsen... Huntsman (HUN), up 3.8% after announcing a $150M share repurchase program... Mellanox (MLNX), up 3.2% after raising third quarter revenue guidance. DOWN AFTER EARNINGS: McCormick (MKC), down 3.4%. ALSO LOWER: Capstone Turbine (CPST), down 26.5% after announcing that its preliminary second quarter earnings were notably below management's expectations and analysts' consensus estimates... Concho Resources (CXO), down 3.9% after 7.7M share Spot Secondary priced at $92.50... AGCO (AGCO), down 3.5% after being downgraded to Sell from Neutral at UBS.
07:37 EDTXOMAXOMA announces agreement for anti-TGFb program with Novartis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use